UNICA IRIS Institutional Research Information System

MULAS, OLGA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 341.109
NA - Nord America 3.255
AS - Asia 1.938
SA - Sud America 400
AF - Africa 58
OC - Oceania 6
Totale 346.766
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 340.096
US - Stati Uniti d'America 3.159
SG - Singapore 791
CN - Cina 600
SE - Svezia 321
BR - Brasile 306
DE - Germania 176
VN - Vietnam 136
KR - Corea 112
FI - Finlandia 104
GB - Regno Unito 94
UA - Ucraina 60
IN - India 58
CA - Canada 57
FR - Francia 56
HK - Hong Kong 53
AR - Argentina 40
AT - Austria 39
NL - Olanda 37
PL - Polonia 36
JP - Giappone 31
MX - Messico 28
ZA - Sudafrica 26
BD - Bangladesh 23
TR - Turchia 18
IR - Iran 16
RU - Federazione Russa 14
CZ - Repubblica Ceca 13
EC - Ecuador 13
SA - Arabia Saudita 13
ES - Italia 12
MA - Marocco 12
AE - Emirati Arabi Uniti 9
ID - Indonesia 9
IQ - Iraq 9
LT - Lituania 8
UY - Uruguay 8
VE - Venezuela 8
BO - Bolivia 7
PK - Pakistan 7
BE - Belgio 6
IE - Irlanda 6
IL - Israele 6
JO - Giordania 6
CL - Cile 5
CO - Colombia 5
EG - Egitto 5
KZ - Kazakistan 5
LB - Libano 5
PE - Perù 5
PH - Filippine 5
AU - Australia 4
MY - Malesia 4
TW - Taiwan 4
UZ - Uzbekistan 4
CH - Svizzera 3
HU - Ungheria 3
NP - Nepal 3
PR - Porto Rico 3
PT - Portogallo 3
RO - Romania 3
TH - Thailandia 3
BG - Bulgaria 2
BY - Bielorussia 2
ET - Etiopia 2
JM - Giamaica 2
KE - Kenya 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PY - Paraguay 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BW - Botswana 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GR - Grecia 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
KG - Kirghizistan 1
KW - Kuwait 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
ML - Mali 1
MT - Malta 1
MW - Malawi 1
NG - Nigeria 1
NI - Nicaragua 1
Totale 346.761
Salva come PNG Salva come JPEG
Città #
Cagliari 317.565
Uta 21.912
Ashburn 484
Singapore 312
Dallas 308
Fairfield 231
Boardman 201
Nyköping 145
Beijing 137
Woodbridge 134
New York 132
Chandler 123
Houston 118
Seattle 117
Los Angeles 114
Cambridge 102
Wilmington 93
Shanghai 83
Hefei 77
Santa Clara 76
Seoul 76
Helsinki 69
Ann Arbor 64
Rome 64
Milan 51
Hong Kong 50
Ho Chi Minh City 41
Munich 39
Boston 33
Incheon 33
Tokyo 30
Buffalo 27
Warsaw 27
São Paulo 26
Atlanta 25
Nuremberg 25
Chicago 23
Frankfurt am Main 23
London 22
The Dalles 22
Toronto 22
Dearborn 21
Redondo Beach 21
San Diego 21
Rio de Janeiro 20
Vienna 20
Hanoi 19
Jacksonville 19
Denver 17
Johannesburg 17
Montreal 17
Dong Ket 16
Turku 16
Redwood City 15
Bologna 14
Brooklyn 14
Lappeenranta 14
Düsseldorf 13
Orem 13
Chennai 12
Nanjing 12
Phoenix 12
Guangzhou 11
Krefeld 11
Poplar 11
Mexico City 10
Buenos Aires 9
Council Bluffs 9
Manchester 9
Ankara 8
Istanbul 8
Mountain View 8
Mumbai 8
Naples 8
Pune 8
Stockholm 8
Turin 8
Alghero 7
Changsha 7
Jeddah 7
Olomouc 7
Porto Alegre 7
Redmond 7
Tianjin 7
Amman 6
Belo Horizonte 6
Berlin 6
Casablanca 6
Haiphong 6
Nanchang 6
Padova 6
Paris 6
Quartu Sant'Elena 6
Salt Lake City 6
Salvador 6
San Francisco 6
Amsterdam 5
Bexley 5
Borghetto di Borbera 5
Brasília 5
Totale 343.874
Salva come PNG Salva come JPEG
Nome #
Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome 240.422
Infectious Complications in Autoimmune Hemolytic Anemia: A Multi-Center Italian Experience 33.686
Association of Hypometilating Agents (HMA) plus Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine 3.441
Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 3.353
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 3.321
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients 3.278
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia 3.190
Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study 2.889
Kir haplotype aa is a possible predictive marker of complete molecular response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2.768
Ruolo del trapianto allogenico nelle talassemie 2.722
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 2.567
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 2.190
Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 2.162
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 2.093
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 2.077
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life 1.911
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice 1.856
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 1.805
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 1.781
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting 1.637
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 1.557
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 1.508
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 1.468
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 987
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors 971
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia 906
Conditioning Regimens in Patients with β-Thalassemia Who Underwent Hematopoietic Stem Cell Transplantation: A Scoping Review 853
Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis 838
Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura 824
Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy 819
Risk and Response-Adapted Treatment in Multiple Myeloma 818
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis 780
Health-Related Quality-of-Life Profile of Pediatric Patients with β Thalassemia after Hematopoietic Stem Cell Transplantation 728
Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials 712
Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study 650
Long-term health-related quality of life in patients with beta-thalassemia after unrelated hematopoietic stem cell transplantation 647
Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension 627
Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine 618
Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib? 615
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 609
Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation 601
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia 589
Low adherence to therapy and co-morbid depressive episodes are independent determinants of early death in people with cancer 581
CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia 572
Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation 571
Adherence to treatment in patients with solid and hematological cancers. Could spiritual and psychological support facilitate optimal adherence? 525
Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report 515
Long-Term Health-Related Quality of Life and Clinical Outcomes in Patients with β-Thalassemia after Splenectomy 478
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML 452
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network 446
Understanding the user's point of view: when the doctor gets sick with cancer and seeks help 437
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 422
Systematic Review and Meta-Analysis of Health-Related Quality of Life in Patients with β-Thalassemia Underwent Hematopoietic Stem Cell Transplantation 420
Extracellular vesicles in the Chronic Myeloid Leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules 410
On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML) 405
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 387
The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia 385
Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform 350
Increase of Arterial Stiffness in Patients with Polycythemia Vera 303
Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase 292
Long-term health-related quality of life and mental health in patients with immune thrombotic thrombocytopenic purpura 263
Response to Dr. Ying Cui comments 236
Thrombotic and Infectious Complications in Patients with Autoimmune Hemolytic Anemia: A Multicenter Observational Study 191
Impact of primary cancer history and molecular landscape in therapy-related myeloid neoplasms 146
Arterial Stiffness as a New Predictor of Clinical Outcome in Patients with Polycythemia Vera 123
Exploring Few-Shot Object Detection on Blood Smear Images: A Case Study of Leukocytes and Schistocytes 82
VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management 75
Beneath the surface in autoimmune hemolytic anemia: pathogenetic networks, therapeutic advancements and open questions 55
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study 24
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologists 5
Totale 347.025
Salva come PNG Salva come JPEG
Categoria #
all - tutte 370.366
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 370.366
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216.180 0 0 0 0 0 1.582 945 886 376 1.043 848 500
2021/20225.564 448 372 235 320 437 382 265 281 533 736 903 652
2022/20237.277 430 861 931 581 539 826 413 599 506 521 712 358
2023/20248.692 389 300 383 540 675 1.558 1.186 666 556 612 866 961
2024/2025298.477 9.454 105.120 175.909 2.949 1.092 1.464 1.375 90 321 188 171 344
2025/20263.017 501 358 638 648 478 394 0 0 0 0 0 0
Totale 347.025